Expertise in
33
conditions

Dr. David A. Marks

Pulmonary Medicine
Pulmonary & Sleep Institute
115 Gallery Cir Ste 102, 
San Antonio, TX 
Accepting New Patients
Offers Telehealth
Expertise in
33
conditions
Pulmonary & Sleep Institute
115 Gallery Cir Ste 102, 
San Antonio, TX 

Overview

David Marks is a Pulmonary Medicine provider practicing medicine in San Antonio, Texas.

Dr. Marks is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Obstructive Sleep Apnea, and Pneumonia.

He is actively involved in clinical research, participating in 4 clinical trials. Dr. Marks is currently accepting new patients.

Specialties

Pulmonary Medicine

Licenses

Hospice and Palliative Medicine in TX

Hospital Affiliations

Baptist Medical Center
Methodist Hospital Stone Oak

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Pulmonary & Sleep Institute
115 Gallery Cir Ste 102, San Antonio, TX 78258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
View 3 Less Clinical Trials
Similar Doctors
Expertise in
7
conditions
Dr. Antonio R. Anzueto
Pulmonary Medicine
Expertise in
7
conditions
Dr. Antonio R. Anzueto
Pulmonary Medicine
Referral may be required

University Of Texas Health Science Center San Antonio

7703 Floyd Curl Dr, 
San Antonio, TX 
 (10.0 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Antonio Anzueto is a Pulmonary Medicine provider practicing medicine in San Antonio, Texas. Dr. Anzueto is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Bronchitis, Hospital-Acquired Pneumonia, and Lung Transplant. Dr. Anzueto is currently accepting new patients.

Expertise in
12
conditions
Dr. Soma S. Jyothula
Pulmonary Medicine
Expertise in
12
conditions
Dr. Soma S. Jyothula
Pulmonary Medicine
Referral may be required

Methodist Heart And Lung Institute - Lung Center

7726 Louis Pasteur Dr, 
San Antonio, TX 
 (9.7 miles away)
Languages Spoken:
English, French, Hindi, Telugu
See accepted insurances
Accepting New Patients

Soma Jyothula is a Pulmonary Medicine provider practicing medicine in San Antonio, Texas. Dr. Jyothula is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Acute Interstitial Pneumonia, Lung Transplant, and Endoscopy. Dr. Jyothula is currently accepting new patients.

Expertise in
2
conditions
Dr. David A. Schenk
Pulmonary Medicine
Expertise in
2
conditions
Dr. David A. Schenk
Pulmonary Medicine
Referral may be required

Sleepcare Consultants PA

7940 Floyd Curl Dr Ste 260, 
San Antonio, TX 
 (10.1 miles away)
210-692-0934
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Schenk is a Pulmonary Medicine provider practicing medicine in San Antonio, Texas. Dr. Schenk is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Obstructive Sleep Apnea and Excessive Daytime Sleepiness. Dr. Schenk is currently accepting new patients.

Frequently Asked Questions about Dr. David A. Marks

Is Dr. David A. Marks a top-rated expert for Lung Metastases?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David A. Marks is classified as an Distinguished expert for Lung Metastases, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David A. Marks specialize in?

While Dr. David A. Marks is a Pulmonary Medicine, they have specific expertise in Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Obstructive Sleep Apnea. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. David A. Marks accept my insurance?

Dr. David A. Marks accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marks's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile